Alaunos Therapeutics plans VLR199 IND or CTA submission in the second half of 2027, with proof-of-concept data expected in 2028. VLR360 also targets 2028 data, while VLR247 or VLR258 IND submission is planned for the first half of 2028.
TCRT · Alaunos Therapeutics, Inc.
The latest filing states the doubt was alleviated.
“These conditions initially raised substantial doubt about the Company’s ability to continue as a going concern. Accordingly, management has concluded that the substantial doubt previously identified about our ability to continue as a going concern has been alleviated.”View the 10-Q filed Nov 16, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 25%
- Last earnings
- May 10, 2023
- Latest filing
- 10-Q · Nov 16
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Alaunos Therapeutics, Inc. asks 2027 stockholders to approve redomestication from Delaware to the Cayman Islands, a reverse split ranging from one new share for every two shares to one for every ten, and an authorized-share increase from 50,000,000 to 400,000,000.
Alaunos Therapeutics, Inc. registered up to 382,090,789 shares for resale by selling stockholders and will receive no proceeds. The registration follows the Velaris Therapeutics, Inc. acquisition closed October 13, 2026 and private placement closed October 14, 2026.
Nasdaq confirmed that the company regained compliance with its $2,500,000 stockholders' equity requirement, so the matter is closed. The November 10, 2026 hearing before the Nasdaq Hearings Panel was cancelled, and the common stock will continue trading on The Nasdaq Capital Market.
Alaunos believes it regained compliance with Nasdaq's $2,500,000 stockholders' equity requirement after a financing with approximately $350.0 million gross proceeds on October 14, 2026. The November 10, 2026 hearing would be cancelled upon Staff confirmation.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TCRT
this stock
Alaunos Therapeutics, Inc.
|
$6.99M | -48.6% | -50.0% | — | 4.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 19
Alaunos Therapeutics plans VLR199 IND or CTA submission in the second half of 2027, with proof-of-concept data expected in 2028. VLR360 also targets 2028 data, while VLR247 or VLR258 IND submission is planned for the first half of 2028.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TCRT | +1.8% | -27.2% | -39.6% | -14.9% | -48.6% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +10.4% | -18.0% | -30.5% | -6.2% | -49.8% |